Vertex to put 200 in field for launch

Share this article:
Vertex Pharmaceuticals said it stands ready to market hepatitis C drug telaprevir, under the brand name Incivek, and the company expected approval could come as early as the end of May.
The Cambridge, MA-based company, which is handling US marketing for the drug, says about 200 field-based employees have been hired to support a potential launch, including a sales team of 115 therapeutic specialists and others, according to a statement. Telaprevir's PDUFA date was May 23. In March, the firm launched a YouTube channel, HepC.tv, and posted the second in a series of animated educational videos in early May.
In April, an FDA advisory committee voted 18-0 to recommend FDA approval. A rival hepatitis C drug from Merck, Victrelis (boceprevir), saw the same positive vote a day earlier. Analysts predict both drugs will reach market and have blockbuster potential.
Which one are physicians more likely to adopt? Market share may depend on the side effect profiles. Telaprevir is more efficacious than boceprevir but may aggravate patients who have skin sensitivities, while boceprevir is more notorious for anemia.
Citing these differences, the Sanford C. Bernstein analyst Tim Anderson wrote in a recent research report that “investor consensus has consistently been that Victrelis may capture ~25% of the hepatitis C market, with telaprevir capturing the remainder.”
Vertex's co-development partner, Johnson & Johnson unit Janssen-Cilag International, is also awaiting a decision from EU regulators. Vertex says it believes that Tibotec, a division of Janssen-Cilag, may receive a response in the second half of this year.
Merck executives say they also expect the FDA to have approved Victrelis by the end of May, and will be ready to begin selling it immediately in the US and shortly thereafter in Europe. In a first-quarter earnings call with analysts, Merck declined to provide details on its launch strategy.
Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric